中南大学学报（医学版）
中南大學學報（醫學版）
중남대학학보（의학판）
JOURNAL OF CENTRAL SOUTH UNIVERSITY (MEDICAL SCIENCES)
2010年
6期
549-556
,共8页
严研%宁晨%周环%杨锡恒%杨天(山)(仑)%刘昭前
嚴研%寧晨%週環%楊錫恆%楊天(山)(崙)%劉昭前
엄연%저신%주배%양석항%양천(산)(륜)%류소전
高血压%SDF-1%SDF1%3A 基因多态性%卡托普利%尼群地平
高血壓%SDF-1%SDF1%3A 基因多態性%卡託普利%尼群地平
고혈압%SDF-1%SDF1%3A 기인다태성%잡탁보리%니군지평
essential hypertension%SDF-1%SDF1 3A genetic polymorphism%captopril%nitrendipine
目的:研究SDF1 3A基因多态性与高血压病易感性和高血压患者应用卡托普利疗效的关系.方法:运用PCR-RFLP对214名高血压患者和228名正常健康个体进行SDF1 3A基因分型. 在39名不同SDF1 3A 基因型的个体中, 13 名高血压患者同时口服卡托普利(25 mg/d) 和尼群地平 (30 mg/d), 12名高血压患者仅口服尼群地平 (30 mg/d), 所有患者连续服药8周以上,14 名正常健康个体没有服任何药物.检测所有受试者的血压变化,以此评估药物的治疗效果.结果:在卡托普利和尼群地平治疗后,SDF1 3A AA+AG基因型或GG基因型的高血压患者中血浆SDF-1水平显著高于正常健康对照组(P<0.05);AA基因型携带者与GG基因型相比较,有较低水平的血浆总蛋白和球蛋白(P<0.05);高血压患者经卡托普利治疗后,AA+AG基因型个体的收缩压降低效果明显好于GG基因型个体 (P<0.05).结论:SDF1 3A遗传多态性可以影响中国汉族高血压患者应用卡托普利的疗效.
目的:研究SDF1 3A基因多態性與高血壓病易感性和高血壓患者應用卡託普利療效的關繫.方法:運用PCR-RFLP對214名高血壓患者和228名正常健康箇體進行SDF1 3A基因分型. 在39名不同SDF1 3A 基因型的箇體中, 13 名高血壓患者同時口服卡託普利(25 mg/d) 和尼群地平 (30 mg/d), 12名高血壓患者僅口服尼群地平 (30 mg/d), 所有患者連續服藥8週以上,14 名正常健康箇體沒有服任何藥物.檢測所有受試者的血壓變化,以此評估藥物的治療效果.結果:在卡託普利和尼群地平治療後,SDF1 3A AA+AG基因型或GG基因型的高血壓患者中血漿SDF-1水平顯著高于正常健康對照組(P<0.05);AA基因型攜帶者與GG基因型相比較,有較低水平的血漿總蛋白和毬蛋白(P<0.05);高血壓患者經卡託普利治療後,AA+AG基因型箇體的收縮壓降低效果明顯好于GG基因型箇體 (P<0.05).結論:SDF1 3A遺傳多態性可以影響中國漢族高血壓患者應用卡託普利的療效.
목적:연구SDF1 3A기인다태성여고혈압병역감성화고혈압환자응용잡탁보리료효적관계.방법:운용PCR-RFLP대214명고혈압환자화228명정상건강개체진행SDF1 3A기인분형. 재39명불동SDF1 3A 기인형적개체중, 13 명고혈압환자동시구복잡탁보리(25 mg/d) 화니군지평 (30 mg/d), 12명고혈압환자부구복니군지평 (30 mg/d), 소유환자련속복약8주이상,14 명정상건강개체몰유복임하약물.검측소유수시자적혈압변화,이차평고약물적치료효과.결과:재잡탁보리화니군지평치료후,SDF1 3A AA+AG기인형혹GG기인형적고혈압환자중혈장SDF-1수평현저고우정상건강대조조(P<0.05);AA기인형휴대자여GG기인형상비교,유교저수평적혈장총단백화구단백(P<0.05);고혈압환자경잡탁보리치료후,AA+AG기인형개체적수축압강저효과명현호우GG기인형개체 (P<0.05).결론:SDF1 3A유전다태성가이영향중국한족고혈압환자응용잡탁보리적료효.
Objective To explore the association of SDF1 3A genetic polymorphism with susceptibility of essential hypertension and captopril efficacy in patients with essential hypertension.Methods A total of 214 patients with essential hypertension and 228 healthy controls were genotyped for SDF1 3A polymorphism by polymerase chain reaction-restriction fragment length polymorphism assay. Among 39 subjects with different SDF1 3A of genotypes, 13 hypertensive patients simultaneously took oral captopril (25 mg/d) and nitrendipine (30 mg/d), and 12 patients orally received nitrendipine alone for 8 consecutive weeks, and 14 healthy controls did not take any agents. The blood pressure of all subjects was measured to evaluate the therapeutic efficacy. Results There was a significant difference in the plasma SDF-1 level in individuals with AA+AG genotypes or GG genotypes of SDF1 3A treated with nitrendipine plus captopril compared with healthy control (P<0.05). Carriers with AA genotypes of SDF1 3A had lower total protein and globulin than those with GG genotypes (P<0.05). After captopril treatment, hypertensive patients with AA+AG genotypes had bigger attenuated systolic blood pressure compared with those with GG genotypes (P<0.05). Conclusion Genetic polymorphism of SDF1 3A could influence the therapeutic efficacy of captopril in Chinese hypertensive patients.
